|
J Biol Chem, Vol. 275, Issue 4, 2607-2612, January 28, 2000
Role of Lumican in the Corneal Epithelium during Wound
Healing*
Shizuya
Saika ,
Atsushi
Shiraishi ,
Satoko
Saika ,
Chia-Yang
Liu ,
James L.
Funderburgh§¶,
Candace W.-C.
Kao ,
Richard L.
Converse , and
Winston W.-Y.
Kao
From the Department of Ophthalmology, University of
Cincinnati Medical Center, Cincinnati, Ohio 45267-0527 and the
§ Department of Ophthalmology, University of Pittsburgh,
Pittsburgh, Pennsylvania 15213
 |
ABSTRACT |
Lumican regulates collagenous matrix
assembly as a keratan sulfate proteoglycan in the cornea and is also
present in the connective tissues of other organs and embryonic corneal
stroma as a glycoprotein. In normal unwounded cornea, lumican is
expressed by stromal keratocytes. Our data show that injured mouse
corneal epithelium ectopically and transiently expresses lumican during
the early phase of wound healing, suggesting a potential lumican
functionality unrelated to regulation of collagen fibrillogenesis,
e.g. modulation of epithelial cell adhesion or migration.
An anti-lumican antibody was found to retard corneal epithelial wound
healing in cultured mouse eyes. Healing of a corneal epithelial injury
in Lum / mice was significantly delayed
compared with Lum+/ mice. These observations
indicate that lumican expressed in injured epithelium may modulate cell
behavior such as adhesion or migration, thus contributing to corneal
epithelial wound healing.
 |
INTRODUCTION |
Rapid re-epithelialization is essential for restoration of
homeostasis in injured tissues; impaired healing of injured epithelium increases the risks of infection and further damage underlying tissues
(1, 2). The cornea provides an ideal model to evaluate interactions of
migrating epithelial cells and the extracellular matrix of the
underlying basement membrane during wound healing because epithelial
injuries of the avascular corneal tissue heal in a bloodless wound
field. Various specific proteins such as vinculin (3), keratins (4),
CD44 hyaluronan receptors (5), and gelatinases and metalloproteinase
inhibitors (6, 7) are up-regulated during corneal epithelial wound
healing. These proteins are believed to modulate cell adhesion or migration.
Lumican belongs to the family of small leucine-rich proteoglycans
(SLRPs)1 that includes
keratocan, mimecan, decorin, biglycan, fibromodulin, epiphycan, and
osteoadherin. In the cornea, lumican, keratocan, and mimecan are
modified with keratan sulfate glycosaminoglycan chains comprising the
keratan sulfate proteoglycans (KSPG) of the stromal extracellular
matrix (8-13). In normal unwounded mouse cornea, lumican mRNA is
expressed in stromal keratocytes (14). Lumican KSPG is a key regulator
of collagen fibrillogenesis, a process critical to corneal
transparency. Mice lacking lumican show an age-dependent
corneal opacity and a high proportion of abnormally thick collagen
fibers in the corneal stroma (15).
Lumican is also widely present as a non- or low-sulfated glycoprotein
in connective tissues of many other organ systems, e.g. skeleton, heart, kidney, and lung (14, 16-18). During mouse embryonic ocular development, lumican is synthesized by keratocytes; detected as
a glycoprotein, not as a KSPG (19); and also transiently expressed by
the corneal epithelium, neural retina, and epidermis (14). These
observations suggest that epithelial tissues possess the capacity to
express lumican under certain conditions.
Several studies have demonstrated that SLRP proteins can modulate
cellular behaviors, i.e. cell migration and proliferation during embryonic development, tissue repair, and tumor growth, in
addition to their extracellular matrix functions as regulators of
tissue hydration and collagen fibrillogenesis (20-22). For example, decorin is one of the SLRP proteins with well characterized functions for modulating cellular behaviors. Decorin protein alters the cell
cycle process in neoplastic cells both by modulating the activities of
growth factors and by direct interaction with a cell-surface receptor
(23, 24). Cultured vascular endothelial cells start to express decorin
after the formation of tube-like structures and also up-regulate
biglycan expression during repair after a damage (25, 26). Under some
pathological conditions, the corneal epithelium shows an increase in
decorin immunoreactivity compared with normal corneal epithelium (27).
Macrophages, on the other hand, express the cell-surface receptor for
lumican. These cells bind the low-sulfated glycoprotein form of
lumican, but not lumican modified with keratan sulfate chains,
suggesting that non- or low-sulfated lumican might provide a scaffold
for macrophages invading injured corneal stroma (28). These
observations prompted us to hypothesize that lumican, like decorin, may
have biological functions for modulating corneal cell behavior such as
adhesion, migration, or proliferation during tissue morphogenesis or
wound healing.
In this study, employing in situ hybridization and
immunocytochemistry, we first showed that migrating corneal epithelial cells ectopically and transiently express lumican during wound healing.
To examine the hypothesis that lumican actively modulates epithelial
wound healing, we then examined the effects of an anti-lumican antibody
on closure of a corneal epithelial defect and the healing of corneal
epithelial defects in lumican-null mice. Our results suggest that
lumican may play a role in epithelial cell migration or adhesion, thus
contributing to corneal epithelial wound healing.
 |
MATERIALS AND METHODS |
Animal Experiments for Histology--
Experimental mice
(n = 52) were anesthetized by intraperitoneal injection
of pentobarbital (70 mg/kg of body weight). The central corneal
epithelium (3 mm in diameter) was demarcated with a trephine and
subsequently removed using a No. 69 Beaver Blade® under a
stereomicroscope as previously reported (29, 30). Neomycin ointment was
topically applied to prevent bacterial infection. The animals were then
killed at specific intervals of healing (1, 2, 4, or 8 h and 1, 2, 3, 5, 7, 14, 21, or 28 days). Each eye was removed, fixed in 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for
48 h, embedded in paraffin, and processed for histology.
In Situ Hybridization of Lumican mRNA--
Paraffin sections
5 µm thick were deparaffinized and processed for in situ
hybridization with sense and antisense riboprobes of mouse lumican and
mouse keratocan as previously reported (12, 31). Finally, the sections
were counterstained with 0.5% neutral red and dehydrated through a
series of ethanol, mounted, and observed under a light microscope.
Preparation of an Epitope-specific Polyclonal Anti-lumican
Antibody--
To prepare the polyclonal antibody, a synthetic
oligopeptide sequence (YYDYDIPLFMYGQISPNC) deduced from mouse lumican
cDNA was conjugated to keyhole limpet hemocyanin (32). The
polyclonal antibodies were raised in rabbits as described previously
(32). Anti-lumican antibodies were purified with an affinity column prepared by conjugating the oligopeptide to Sulfolink®
(Pierce) using the procedures recommended by the manufacturer.
Western Blotting to Characterize the Anti-lumican
Antibody--
Mouse corneal KSPGs and recombinant mouse lumican
expressed in Escherichia coli were prepared as described
previously (33), and the core proteins of the KSPGs were deglycosylated
by treatment with N-glycanase (9). Two µg of total protein
was subjected to SDS-polyacrylamide gel electrophoresis and
electrotransferred to polyvinylidene difluoride membranes (9). Lumican
was detected by immunostaining with the anti-lumican antibody (10 µg/ml) using an indirect method as described previously (32).
Immunohistochemistry--
To locate lumican protein, paraffin
sections from normal and injured corneas healed for various periods of
times were subjected to immunohistochemistry with the epitope-specific
anti-lumican antibody (10 µg/ml) and nonimmune rabbit IgG (control)
as described previously (34).
Transmission Electron Microscopy--
Corneas were fixed in
2.0% glutaraldehyde in 0.1 M phosphate buffer
for 24 h at 4 °C. The samples were then post-fixed in 2.0%
osmium tetroxide, rinsed in 0.1 M phosphate buffer, and
embedded in Epon 812 (Quetol 812, Nissin EM, Tokyo, Japan). Ultrathin
sections were stained with uranyl acetate and lead citrate and observed by transmission electron microscopy (35).
In Vitro Wound Healing of the Corneal Epithelia of Organ-cultured
Mouse Eyes--
To examine whether the anti-lumican antibody inhibits
corneal epithelial wound healing, we developed an in vitro
wound healing model using cultured mouse eyes. A central corneal
epithelial defect (2 mm in diameter) was produced in both eyes of 38 anesthetized wild-type mice under a stereomicroscope. Our preliminary
immunohistochemical examination with a rat monoclonal anti-laminin
antibody (X50, BIODESIGN International, Kennebunkport, ME) showed the
presence of the uninterrupted epithelial basement membrane immediately after the epithelial scraping (data not shown). The animals were killed
immediately after the epithelial débridement. Each eyeball was
enucleated and cultured in Dulbecco's modified Eagle's medium (Life
Technologies, Inc.) supplemented with 1.4% fetal calf serum and 50 µg/ml gentamycin in 10% CO2 and 90% air at 37 °C
with the anti-lumican antibody (40 µg/ml) or normal rabbit IgG (40 µg/ml; Sigma). Both the antibody and control IgG were dialyzed
against phosphate-buffered saline for 24 h before application.
After incubation for 48 h, each eye was stained with fluorescein
and photographed using a stereomicroscope. The healing of epithelial
defects was categorized into three groups: 1) healed, 2) resurfaced
with regenerated epithelium and punctate epithelial staining, and 3)
not healed with remaining defects. Distribution of individuals in these
groups was statistically analyzed using the 2 test.
Gene Targeting and Creation of Mice Lacking the Lumican Gene
(Lum)--
To examine the in vivo role of lumican in
corneal epithelial wound healing, we prepared lumican-null mice via
gene-targeting techniques. The lumican gene-targeting construct
contains 4.1 kb of 5'-homology (SacI/XbaI
fragment), the 2.9-kb pgk-hprt cassette, 1.8 kb
of 3'-homology (XhoI/BamHI fragment), and a
2.0-kb pMC-tk cassette in the pBluescript vector. The
XbaI/XhoI fragment containing 481 base pairs of
exon 2 was deleted and replaced with a pgk-hprt cassette. The targeting vector was transfected into
hprt-negative E14TG2a ES cells derived from mouse strain
129/Sv by electroporation using a Bio-Rad Gene-Pulser. A targeted ES
cell clone (frequency of 1:186) was identified by Southern blot
hybridization and used to generate chimeric mice in our Gene Targeting
Core Facility (University of Cincinnati). C57BL/6J blastocysts injected
with 10-12 ES cells were implanted in pseudopregnant F1(CBA × C57BL/6) foster mothers (Jackson ImmunoResearch Laboratories, Inc.).
Chimeric mice, identified by agouti coat color, were mated with
C57BL/6J mice. Agouti coat-colored offspring were tested for the
presence of the targeted locus by polymerase chain reaction (PCR) and
Southern hybridization as described previously (12). To distinguish
between individuals with none, one, or two copies of the mutant gene, we designed three primers in a PCR for detection of the wild type (primer 1, 5'-TACTTCAAGCGCTTCAC-3'; and primer 2, antisense
5'-CAAGTTCATTGACCTCCAGG-3'; 190 base pairs) and mutant (primers 2 and
3, antisense 5'-CGAGACTAGTGAGACGTGCT-3' of the hprt
minigene; 381 base pairs), respectively. Northern hybridization,
in situ hybridization, and immunohistochemistry were used to
determine the phenotypes of littermates using the procedures described above.
Healing of Corneal Epithelial Defects in Lumican-deficient
Mice--
Age-matched littermates were used as controls. Two-month-old
Lum+/ (n = 22) and
Lum / (n = 16) mice were
anesthetized and subjected to 2-mm corneal epithelial débridement
as described above. Our preliminary immunohistochemistry results showed
the presence of the non-interrupted epithelial basement membrane
immediately after epithelial scraping in both Lum+/ and Lum / mice
as described above. The injured corneas were stained with fluorescein
and photographed with a stereomicroscope every 24 h, beginning
immediately after wounding, to evaluate the re-epithelialization and to
detect any sign of infection. Healing of epithelial defects was graded
and statistically analyzed in a manner similar to the in
vitro wound healing experiment described above.
 |
RESULTS |
Characterization of Polyclonal Anti-Lumican Antibody--
We
prepared epitope-specific anti-lumican antibody as described under
"Methods and Methods." Western blot immune analysis was used to
characterize an affinity-purified rabbit polyclonal antibody directed
against the N-terminal oligopeptide of mouse lumican
(YYDYDIPLFMYGQISPNC). This sequence is not found in keratocan or other
members of the SLRP family (12, 27). Fig.
1 demonstrates that the antibodies
reacted with recombinant lumican prepared from the expression clone of
E. coli (lane 1) and a 41-kDa KSPG core protein
isolated from mouse corneas after deglycosylation with
N-glycanase (lane 2).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 1.
Western blot characterization of the
anti-lumican antibody. Recombinant mouse lumican and mouse KSPG)
core protein were separated by SDS-polyacrylamide gel electrophoresis
and transferred to a polyvinylidene difluoride membrane. The membrane
was immunostained with the affinity-purified polyclonal anti-lumican
antibody (10 µg/ml). The antibody reacted to recombinant lumican
(lane 1) and deglycosylated mouse KSPG core protein (~41
kDa) (lane 2).
|
|
Phenotypic Changes in Mice Lacking Lumican--
Fig.
2A summarizes the strategy
used to ablate the lumican gene in mice via gene-targeting techniques.
A targeting construct containing the human hypoxanthine
phosphoribosyltransferase and herpes simplex virus thymidine kinase
genes was prepared as described under "Materials and Methods." The
genotypes of the lumican knockout mice were determined by PCR and
Southern blot analysis (Fig. 2, B and C).
Northern hybridization, in situ hybridization, and
immunohistochemistry revealed no expression of lumican mRNA and the
absence of lumican protein antigens in Lum /
mice (Fig. 2, D and E). This phenotype of the
lumican-null mice is indicative of a loss of lumican expression rather
than the presence of a dominant-negative mutation. The homozygous
mutant mice were born alive in the expected mendelian ratio and were fertile. The skin of adult Lum / mice was
fragile as evidenced by the disruption of skin when experimental
animals were killed by cervical dislocation. The back skin hairs of
adult Lum / mice were disarranged. It is of
interest to note that the male lumican-null mice appear to produce a
smaller number of offspring compared with female
Lum / mice when they are mated with wild-type
mice. The reason for the phenomenon is not known. However, it could be
secondary to the fragile skin phenotype.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 2.
A, targeted disruption of the mouse
lumican gene (Lum) and phenotyping the lumican knockout
mice. Panel 1, shown is a restriction enzyme map of the
Lum gene. Panel 2, a 5.0-kb
SacI/BamHI fragment was used to generate the
replacement targeting vector. A 481-base pair
XbaI/XhoI fragment from the exon 2 was deleted
and replaced with a pgkHPRTpA cassette in the antisense orientation
with respect to the Lum gene. In addition, a
pMC-tk cassette was placed on the 3'-end of the targeting
vector. Panel 3, shown is the targeted allele after
homologous recombination. Panel 4, shown are the expected
sizes of restriction fragments detected by a 5'- or 3'-probe.
B, autoradiography of Southern blot hybridization. DNA from
one litter of a Lum-targeted heterozygous intercross was
digested with SpeI or XbaI and separated by 0.8%
agarose gel electrophoresis. The DNA was then subjected to Southern
blot hybridization with a 5'-probe (SpeI digestion). The
5.0- and 7.0-kb bands represent wild-type and mutant alleles,
respectively. Hybridization with 3'-probes yielded similar results (not
shown). C, genotyping of offspring from the heterozygous
mating by PCR. PCR products amplified from the DNA were resolved by 4%
NuSieve/Sea Kem (3:1) agarose gel electrophoresis. D,
Northern hybridization of lumican mRNA from eyes of
lumican-deficient mice. Lumican mRNA was not detected in
Lum / mice with 32P-labeled mouse
lumican probes. 28 S and 18 S ribosomal RNAs indicate the quality and
quantity of RNA samples. E, immunohistochemistry
(panels 1 and 2) and in situ
hybridization (panels 3 and 4) of lumican protein
and mRNA in a Lum+/ or
Lum / mouse. In situ hybridization
and immunohistochemistry were performed to further characterize the
phenotype of the mice. The corneal stroma showed immunoreactivity for
lumican (panel 1), and keratocytes expressed lumican
mRNA (panel 3) in a Lum+/
mouse, whereas the stroma had no lumican protein (panel 2)
and mRNA (panel 4) in a Lum /
mouse. pgk, phosphoglycerate kinase I gene; pr,
promoter; hprt, hypoxanthine phosphoribosyltransferase;
pA, polyadenylation signal sequence; tk,
thymidine kinase gene.
|
|
Fig. 3 demonstrates that abnormal thick
collagen fibers were seen in the posterior corneal stromata of
lumican-null mice 4 months old, whereas the anterior stromal collagen
fibers appeared normal (data not shown). These larger collagen fibrils
were not observed in the stromata of younger lumican-null mice. The
corneal haze as recognized with a stereomicroscope was concurrent with the presence of a disorganized collagenous matrix in lumican-null mice.
This phenotype is consistent with the observations reported by
Chakravarti et al. (15).

View larger version (135K):
[in this window]
[in a new window]
|
Fig. 3.
Electron micrographs of corneal
stromata. Corneas of 4-month-old Lum+/
and Lum / mice were subjected to transmission
electron microscopy. A, collagenous matrix in the posterior
corneal stroma from a Lum+/ mouse. Collagen
fibrils are uniform in size and consistent in inter-fibril distances.
B, irregular large collagen fibrils from lateral fusion in
the posterior stroma of a Lum / mouse.
Bar is equal to 100 and 50 nm in the panels and
insets, respectively.
|
|
Clinical and Histological Observations of Eyes after
Epithelial Débridement in Wild-type Mice--
A corneal
epithelial defect (3 mm in diameter) was created as described under
"Materials and Methods." One day after injury, the central corneal
stroma was still exposed, and a healing epithelium was observed in the
periphery. Polymorphonuclear leukocytes were seen in the healing stroma
at day 1 after injury. By day 3, the defect was covered by regenerated
epithelia in all corneas examined (data not shown).
In Situ Hybridization Detection of Lumican mRNA--
As shown
in Fig. 4A, lumican mRNA
was detected in the stromal keratocytes, but not in epithelial cells of
uninjured corneas. Injured corneal epithelium expressed lumican
mRNA from 8 h until 3 days after the epithelial
débridement (Fig. 4, C-E and G-I). Seven
days after injury, corneal epithelial defects were healed with a
stratified multicellular epithelium that did not yield positive
hybridization signals (Fig. 4J). No signals were seen with
sense probes (Fig. 4, B and F). Neither lens
epithelial cells nor neural retina hybridized to the lumican antisense
riboprobes (data not shown). Keratocan mRNA was not detected in
either normal or migrating epithelium, but was present in keratocytes
(data not shown).

View larger version (109K):
[in this window]
[in a new window]
|
Fig. 4.
In situ hybridization detection of
lumican mRNAs in normal and healing mouse corneas. An
epithelial defect (3 mm in diameter) was created in corneas of
anesthetized mice. The animals were killed after specific intervals of
healing, and corneas were processed for in situ
hybridization with sense or antisense lumican riboprobes. In a normal
mouse cornea, lumican mRNAs were expressed by keratocytes
(A, arrowhead). No signals were seen with sense
probes (B). Expression patterns of lumican mRNAs in
healing mouse corneas after 3-mm-diameter epithelial débridement
are shown (C-J). Two and 4 h after injury, no signals
for lumican mRNA were observed in injured epithelium (C
and D). Signals for lumican mRNAs were detected in
injured corneal epithelia (open arrows) and in keratocytes
(arrowheads) at 8 h (E) and at 1 (G), 2 (H), and 3 (I) day(s) after
epithelial débridement, whereas no signals were seen with sense
probes (F). At day 7, regenerated epithelium was negative
for lumican mRNA, whereas keratocytes were positive (J).
A-F, without counterstaining; G-J,
counterstained with 0.5% neutral red. The arrows indicate
the edge of the injured or healing epithelium. Bar = 100 µm.
|
|
Immunohistochemistry--
In tissue sections, the anti-lumican
antibody stained normal corneal stroma (Fig.
5A) as well as sclera and
dermal connective tissue of the eyelid (data not shown). Lumican
staining in the corneal stroma was more intense in the posterior than
in the anterior stroma. The anti-lumican antibody did not react to the
epithelium or basement membrane of uninjured cornea (Fig.
5A) or other ocular tissues, e.g. neural retina,
lens epithelial cells, and the epidermis of the eyelid (data not
shown). After wounding, faint lumican intracellular immunoreactivity
was seen in migrating epithelium 1 day after the injury (Fig.
5C). The healing epithelia at days 2 and 3 were strongly
labeled by the antibodies (Fig. 5, D and E). At
day 3, lumican immunoreactivity was observed mainly in the cytoplasm of
basal cells of regenerated epithelium. The antibodies also reacted to
the basement membrane underlying the basal epithelial cells of injured
corneas healed for 2 and 3 days. After day 7, the epithelium was
negative for lumican protein (Fig. 5F).

View larger version (120K):
[in this window]
[in a new window]
|
Fig. 5.
Immunolocalization of lumican protein in
mouse corneas with an anti-lumican antibody. An epithelial defect
(3 mm in diameter) was created in corneas of anesthetized mice. The
animals were killed after specific intervals of healing, and corneas
were processed for immunohistochemistry with the anti-lumican
antibody (10 µg/ml). In a normal mouse cornea, lumican protein was
detected in the corneal stroma (A). No staining was seen in
the control (B). Localization of lumican protein in healing
mouse corneas after an epithelial débridement is shown in
C-F. Very faint lumican immunoreactivity was detected in
healing corneal epithelium (thick arrow) at day 1 (C) and was obviously observed in healing epithelia
(open arrows) at days 2 (D) and 3 (E).
Regenerated epithelium at day 7 (F) was negative for lumican
protein. A-F were counterstained with hematoxylin. The
thin arrow indicates the edge of the healing epithelium.
Bar = 20 µm.
|
|
Effect of the Anti-lumican Antibody on Epithelial
Healing--
Epithelial defects (2 mm in diameter) closed in ~48 h
in the in vitro wound healing model. As shown in Table
I, the anti-lumican antibody (40 µg/ml)
significantly inhibited epithelial healing as compared with control
normal rabbit IgG (40 µg/ml). Preliminary observations revealed that
the addition of mitomycin C (0.1 µg/ml) to the culture medium did not
retard the closure of the epithelial defect, but did inhibit epithelial
proliferation as judged by incorporation of bromodeoxyuridine (data not
shown). These observations are consistent with the notion that lumican
may have a role in epithelial cell migration during wound healing.
View this table:
[in this window]
[in a new window]
|
Table I
Wound healing of a corneal epithelial defect in organ-cultured
mouse eyes
Results are from organ cultures of mouse eyes with a 2-mm-diameter
epithelial defect in the presence of the anti-lumican antibody (40 µg/ml) or normal rabbit IgG (40 µg/ml) for 48 h. Healed
indicates completely resurfaced; punctate, resurfaced by regenerated
epithelium with punctate staining; and defect, not healed with
remaining defects.
|
|
Healing of Epithelial Defects in Lumican-deficient Mice--
Fig.
6 and Table
II summarize the wound healing of a
2-mm-diameter central corneal epithelial defect in lumican-null mice. One day after injury, the number of corneas completely resurfaced was
significantly higher in Lum+/ mice than in
Lum / mice. Two days after injury, 19 of 22 injured eyes completely re-epithelialized and became transparent in
Lum+/ mice, whereas 8 of 16 eyes healed in
Lum / mice. At day 3, 5 of 16 corneas of
Lum / mice still had epithelial defects,
whereas all epithelial defects in the corneas of
Lum+/ mice had healed. At day 5, the
epithelial defects had healed in Lum /
mice.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 6.
Wound healing of a corneal epithelial defect
in Lum+/ (panels
1-3) and
Lum /
(panels 4-9) mice. An epithelial defect (2 mm in diameter) was
created at the center of the corneas (panels 1,
4, and 7). After 1 day, no epithelial defect was
detected in Lum+/ mice (panel 2),
and a central non-resurfaced area stained with fluorescein was seen in
each Lum / mouse (panels 5 and
8). At day 2, no epithelial staining was observed in
Lum+/ (panel 3) or
Lum / (panel 6) mice, whereas
punctate fluorescein staining (arrowheads) was detected in
the regenerated central epithelium of many
Lum / mice (panel 9).
Bar = 1 mm.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Wound healing of a corneal epithelial defect in lumican-deficient mice
A 2-mm epithelial defect was created at the center of the cornea of a
Lum+/ or Lum / mouse with a No. 69 Beaver Blade®
and was allowed to heal as described under "Materials and Methods."
|
|
 |
DISCUSSION |
The evidence available suggests that SLRP proteins are key
regulatory molecules of collagen fibrillogenesis (36). Null mutants of
SLRP family proteins, i.e. decorin, biglycan, fibromodulin, and lumican, are manifested by malfunctions of connective tissues associated with abnormal extracellular matrix, i.e. fragile
skin, cloudy cornea, and thick collagen fibrils (15, 37-39). Our
lumican-null mice have phenotypes that closely resemble those described
by Chakravarti et al. (15). It is of interest that the
results of the present study imply that lumican, in addition to serving as a regulator of collagen fibrillogenesis, may modulate epithelial cell migration during corneal wound healing. We observed an ectopic and
transient expression of lumican mRNA in healing mouse corneal epithelium as early as 8 h after an epithelial débridement
(Fig. 4). An obvious accumulation of lumican protein occurred in the basal epithelial cells and the basement membrane of injured epithelia after 2-3 days of healing (Fig. 5). The observation is consistent with
the notion that lumican is secreted by the epithelial cells. The
up-regulated lumican synthesis can account for the intracellular immunoreactivity observed in the healing epithelium. The addition of
anti-lumican antibodies to the culture medium retarded closure of an
epithelial defect in healing wounds in vitro (Table I), and
Lum / mice lacking lumican showed delayed
re-epithelialization of corneal epithelial defects in vivo
(Fig. 6 and Table II). These observations are consistent with the
hypothesis that lumican expressed in injured corneal epithelium
modulates corneal epithelial wound healing. Interestingly, keratocan,
another member of SLRP family closely related to lumican, was not
expressed by injured corneal epithelium, but only by stromal
keratocytes. This finding indicates that these two KSPG proteins are
transcriptionally regulated differently, albeit both are major KSPG
constituents of the corneal stroma extracellular matrix.
Several other studies have presented results consistent with
epithelial expression of lumican. In chick, KSPG precursor protein synthesis by organ culture of corneal epithelia amounts to 7.2% of the
protein synthesis of organ-cultured whole corneas (40). Moreover, the
basal and suprabasal cells of the hyperproliferative corneal epithelium
of a Corn1 mouse (41), a mutant mouse characterized by
hyperplasia of the central corneal epithelium associated with corneal
neovascularization, express lumican
mRNA.2 In the adult
cornea, lumican exists as KSPG; however, in non-corneal tissues as well
as in embryonic and wounded corneas, lumican is found as a low- or
non-sulfated glycoprotein (14, 18, 42). Rat corneal epithelium was
previously shown to transiently up-regulate glycoprotein synthesis as a
result of wounding (43, 44). This glycoprotein may represent the
lumican induction described in the present study. Our data do not
directly elucidate the mechanism by which lumican may modulate
epithelial cell adhesion or migration. Recently, a novel bone KSPG core
protein of the SLRP family, osteoadherin, was found to be distributed
in bovine fetal rib growth plate and in newly deposited bone in
vivo (45). It has been demonstrated that osteoadherin can mediate
cell attachment via binding by v 3 integrin in vitro (45). A divalent
cation-dependent lumican cell-surface receptor has been
identified in macrophages, implying possible binding of integrin to
lumican. Binding of cells to lumican, however, is strongly inhibited by
the presence of keratan sulfate chains on lumican (28). It is possible
that lumican transiently expressed by injured epithelium might interact
with integrin receptors of epithelial cells; thus, it may facilitate
healing of epithelial defects. However, the presence of such
cell-surface receptor(s) of lumican in corneal epithelial cells is to
be proven in future studies. Our unpublished
observations3 by transmission electron
microscopy revealed that there is no apparent difference in the
ultrastructure of the basement membrane and hemidesmosomes of unwounded
corneas and of those of 1 or 2 months after an epithelial
débridement in Lum+/ and
Lum / mice. These observations are consistent
with the notion that impaired epithelial wound healing was not caused
by structural abnormalities of the denuded corneal surface due to the
absence of lumican in Lum / mice.
Our finding that lumican may have a role in modulating corneal
wound healing of epithelial defects is consistent with an emerging body
of data showing that SLRP proteins not only serve as regulators of
collagenous extracellular matrix assembly, but also have biological roles involving direct interactions with cells. These include mediation
of cell migration and proliferation (20-24). Laser surgery to correct
refractive errors is a widely practiced procedure, after which rapid
re-epithelialization is required to avoid complications such as
infection or induction of scar tissue. The findings reported here
suggest the possible therapeutic use of lumican protein in topical
administration after such surgery or in the treatment of corneal or
skin wounds.
 |
FOOTNOTES |
*
This work was supported by Grants EY10556 and EY11845 from
the National Institutes of Health and the Ohio Lion's Eye Research Foundation (Columbus, OH) (to W. W.-Y. K); Grant EY09368 from the
National Institutes of Health and Grant KS-96-GS-2 from the American
Heart Association, Kansas Affiliate (to J. L. F); the Ministry of
Education, Culture, and Science of Japan, the Nippon Eye Bank
Association Fund (Tokyo, Japan), and a Bausch-Lomb overseas research
fellowship award (Tokyo) (to S. S).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Jules and Doris Stein Research to Prevent Blindness Professor
of Ophthalmology.
To whom correspondence and reprint requests should be
addressed: Dept. of Ophthalmology, University of Cincinnati Medical Center, Health Professions Bldg., Suite 350, ML0527, Eden and Bethesda
Aves., Cincinnati, OH 45267-0527. Tel.: 513-558-5151; Fax:
513-558-3108; E-mail: Winston.Kao@UC.EDU.
2
I.-J. Wong, S. Saika, C.-Y. Liu, C. W.-C.
Kao, R. S. Smith, P. M. Nishina, J. P. Sundberg, and W. W.-Y. Kao,
unpublished observations.
3
S. Saika, C.-Y. Lin, and W. W.-Y. Kao,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
SLRPs, small
leucine-rich proteoglycans;
KSPG, keratan sulfate proteoglycan;
kb, kilobase(s);
PCR, polymerase chain reaction.
 |
REFERENCES |
| 1.
|
Brown, D. L.,
Kao, W. W.-Y.,
and Greenhalgh, D. G.
(1997)
Surgery (St. Louis)
121,
372-380[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Wilson, S. E.
(1997)
J. Refract. Surg.
13,
171-175[Medline]
[Order article via Infotrieve]
|
| 3.
|
Zieske, J. D.,
Bukusoglu, G.,
and Gipson, I. K.
(1989)
J. Cell Biol.
109,
571-576[Abstract/Free Full Text]
|
| 4.
|
Yu, F. X.,
Gipson, I. K.,
and Guo, Y.
(1995)
Invest. Ophthalmol. Visual Sci.
36,
1997-2007[Abstract/Free Full Text]
|
| 5.
|
Yu, F. X.,
Guo, J.,
and Zhang, Q.
(1998)
Invest. Ophthalmol. Visual Sci.
39,
710-717[Abstract/Free Full Text]
|
| 6.
|
Inoue, M.,
Kratz, G.,
Haegerstrand, A.,
and Stahle-Backdahl, M.
(1995)
J. Invest. Dermatol.
104,
479-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Saarialho-Kere, U. K.,
Kovacs, S. O.,
Pentland, A. P.,
Olerud, J. E.,
Welgus, H. G.,
and Parks, W. C.
(1993)
J. Clin. Invest.
92,
2858-2866
|
| 8.
|
Corpuz, L. M.,
Funderburgh, J. L.,
Funderburgh, M. L.,
Bottomley, G. S.,
Prakash, S.,
and Conrad, G. W.
(1996)
J. Biol. Chem.
271,
9759-9763[Abstract/Free Full Text]
|
| 9.
|
Funderburgh, J. L.,
and Conrad, G. W.
(1990)
J. Biol. Chem.
265,
8297-8303[Abstract/Free Full Text]
|
| 10.
|
Funderburgh, J. L.,
Corpuz, L. M.,
Roth, M. R.,
Funderburgh, M. L.,
Tasheva, E. S.,
and Conrad, G. W.
(1997)
J. Biol. Chem.
272,
28089-28095[Abstract/Free Full Text]
|
| 11.
|
Funderburgh, J. L.,
Funderburgh, M. L.,
Brown, S. J.,
Vergnes, J. P.,
Hassell, J. R.,
Mann, M. M.,
and Conrad, G. W.
(1993)
J. Biol. Chem.
268,
11874-11880[Abstract/Free Full Text]
|
| 12.
|
Liu, C.-Y.,
Shiraishi, A.,
Kao, C. W.-C.,
Converse, R. L.,
Funderburgh, J. L.,
Corpuz, L. M.,
Conrad, G. W.,
and Kao, W. W.-Y.
(1998)
J. Biol. Chem.
273,
22584-22588[Abstract/Free Full Text]
|
| 13.
|
Scott, J. E.
(1996)
Biochemistry
35,
8795-8799[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ying, S.,
Shiraishi, A.,
Kao, C. W.-C.,
Converse, R. L.,
Funderburgh, J. L.,
Swiergiel, J.,
Roth, M. R.,
Conrad, G. W.,
and Kao, W. W.-Y.
(1997)
J. Biol. Chem.
272,
30306-30313[Abstract/Free Full Text]
|
| 15.
|
Chakravarti, S.,
Magnuson, T.,
Lass, J. H.,
Jepsen, K. J.,
LaMantia, C.,
and Carroll, H.
(1998)
J. Cell Biol.
141,
1277-1286[Abstract/Free Full Text]
|
| 16.
|
Funderburgh, J. L.,
Funderburgh, M. L.,
Mann, M. M.,
and Conrad, G. W.
(1991)
J. Biol. Chem.
266,
24773-24777[Abstract/Free Full Text]
|
| 17.
|
Funderburgh, J. L.,
Caterson, B.,
and Conrad, G. W.
(1987)
J. Biol. Chem.
262,
11634-11640[Abstract/Free Full Text]
|
| 18.
|
Grover, J.,
Chen, X. N.,
Korenberg, J. R.,
and Roughley, P. J.
(1995)
J. Biol. Chem.
270,
21942-21949[Abstract/Free Full Text]
|
| 19.
|
Cornuet, P. K.,
Blochberger, T. C.,
and Hassell, J. R.
(1994)
Invest. Ophthalmol. Visual Sci.
35,
870-877[Abstract/Free Full Text]
|
| 20.
|
Fullwood, N. J.,
Davies, Y.,
Nieduszynski, I. A.,
Marcyniuk, B.,
Ridgway, A. E.,
and Quantock, A. J.
(1996)
Invest. Ophthalmol. Visual Sci.
37,
1256-1270[Abstract/Free Full Text]
|
| 21.
|
Iozzo, R. V.
(1997)
Crit. Rev. Biochem. Mol. Biol.
32,
141-174[Medline]
[Order article via Infotrieve]
|
| 22.
|
Wight, T. N.,
Kinsella, M. G.,
and Qwarnstrom, E. E.
(1992)
Curr. Opin. Cell Biol.
4,
793-801[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Iozzo, R. V.,
Moscatello, D. K.,
McQuillan, D. J.,
and Eichstetter, I.
(1999)
J. Biol. Chem.
274,
4489-4492[Abstract/Free Full Text]
|
| 24.
|
Moscatello, D. K.,
Santra, M.,
Mann, D. M.,
McQuillan, D. J.,
Wong, A. J.,
and Iozzo, R. V.
(1998)
J. Clin. Invest
101,
406-412[Medline]
[Order article via Infotrieve]
|
| 25.
|
Jarvelainen, H. T.,
Iruela-Arispe, M. L.,
Kinsella, M. G.,
Sandell, L. J.,
Sage, E. H.,
and Wight, T. N.
(1992)
Exp. Cell Res.
203,
395-401[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Jarvelainen, H. T.,
Kinsella, M. G.,
Wight, T. N.,
and Sandell, L. J.
(1991)
J. Biol. Chem.
266,
23274-23281[Abstract/Free Full Text]
|
| 27.
|
Funderburgh, J. L.,
Hevelone, N. D.,
Roth, M. R.,
Funderburgh, M. L.,
Rodrigues, M. R.,
Nirankari, V. S.,
and Conrad, G. W.
(1998)
Invest. Ophthalmol. Visual Sci.
39,
1957-1964[Abstract/Free Full Text]
|
| 28.
|
Funderburgh, J. L.,
Mitschler, R. R.,
Funderburgh, M. L.,
Roth, M. R.,
Chapes, S. K.,
and Conrad, G. W.
(1997)
Invest. Ophthalmol. Visual Sci.
38,
1159-1167[Abstract/Free Full Text]
|
| 29.
|
Kao, W. W.-Y.,
Kao, C. W.-C.,
Kaufman, A. H.,
Kombrinck, K. W.,
Converse, R. L.,
Good, W. V.,
Bugge, T. H.,
and Degen, J. L.
(1998)
Invest. Ophthalmol. Visual Sci.
39,
502-508[Abstract/Free Full Text]
|
| 30.
|
Kao, W. W.-Y.,
Liu, C.-Y.,
Converse, R. L.,
Shiraishi, A.,
Kao, C. W.-C.,
Ishizaki, M.,
Doetschman, T.,
and Duffy, J.
(1996)
Invest. Ophthalmol. Visual Sci.
37,
2572-2584[Abstract/Free Full Text]
|
| 31.
|
Delorenzi, N. J.,
Sculsky, G.,
and Gatti, C. A.
(1996)
Int. J. Biol. Macromol.
19,
15-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Moyer, P. D.,
Kaufman, A. H.,
Zhang, Z.,
Kao, C. W.-C.,
Spaulding, A. G.,
and Kao, W. W.-Y.
(1996)
Differentiation
60,
31-38[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Funderburgh, J. L.,
Funderburgh, M. L.,
Hevelone, N. D.,
Stech, M. E.,
Justice, M. J.,
Liu, C.-Y.,
Kao, W. W.-Y.,
and Conrad, G. W.
(1995)
Invest. Ophthalmol. Visual Sci.
36,
2296-2303[Abstract/Free Full Text]
|
| 34.
|
Ishizaki, M.,
Zhu, G.,
Haseba, T.,
Shafer, S. S.,
and Kao, W. W.-Y.Y.
(1993)
Invest. Ophthalmol. Visual Sci.
34,
3320-3328[Abstract/Free Full Text]
|
| 35.
|
Saika, S.,
Shimezaki, M.,
Ohkawa, K.,
Okada, Y.,
Tawara, A.,
Ohnishi, Y.,
Ooshima, A.,
Kimura, M.,
Kurumatani, N.,
Naka, H.,
Awata, T.,
and Kao, W. W.-Y.
(1998)
Curr. Eye Res.
17,
1049-1057[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Iozzo, R.,
and Murdoch, A. D.
(1996)
FASEB J.
10,
598-614[Abstract]
|
| 37.
|
Danielson, K. G.,
Baribault, H.,
Holmes, D. F.,
Graham, H.,
Kadler, K. E.,
and Iozzo, R. V.
(1997)
J. Cell Biol.
136,
729-743[Abstract/Free Full Text]
|
| 38.
|
Svensson, L.,
Aszodi, A.,
Reinholt, F. P.,
Fassler, R.,
Heinegard, D.,
and Oldberg, A.
(1999)
J. Biol. Chem.
274,
9636-9647[Abstract/Free Full Text]
|
| 39.
|
Xu, T.,
Bianco, P.,
Fisher, L. W.,
Longenecker, G.,
Smith, E.,
Goldstein, S.,
Bonadio, J.,
Boskey, A.,
Heegaard, A. M.,
Sommer, B.,
Satomura, K.,
Dominguez, P.,
Zhao, C.,
Kulkarni, A. B.,
Robey, P. G.,
and Young, M. F.
(1998)
Nat. Genet.
20,
78-82[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Schrecengost, P. K.,
Blochberger, T. C.,
and Hassell, J. R.
(1992)
Arch. Biochem. Biophys.
292,
54-61[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Smith, R. S.,
Hawes, N. L.,
Kuhlmann, S. D.,
Heckenlively, J. R.,
Chang, B.,
Roderick, T. H.,
and Sundberg, J. P.
(1996)
Invest. Ophthalmol. Visual Sci.
37,
397-404[Abstract/Free Full Text]
|
| 42.
|
Funderburgh, J. L.,
Funderburgh, M. L.,
Mann, M. M.,
and Conrad, G. W.
(1991)
J. Biol. Chem.
266,
14226-14231[Abstract/Free Full Text]
|
| 43.
|
Gipson, I. K.,
and Kiorpes, T. C.
(1982)
Dev. Biol.
92,
259-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Gipson, I. K.,
Kiorpes, T. C.,
and Brennan, S. J.
(1984)
Dev. Biol.
101,
212-220[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Wendel, M.,
Sommarin, Y.,
and Heinegard, D.
(1998)
J. Cell Biol.
141,
839-847[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Zhang, S. Chen, S. Goldoni, B. W. Calder, H. C. Simpson, R. T. Owens, D. J. McQuillan, M. F. Young, R. V. Iozzo, and D. E. Birk
Genetic Evidence for the Coordinated Regulation of Collagen Fibrillogenesis in the Cornea by Decorin and Biglycan
J. Biol. Chem.,
March 27, 2009;
284(13):
8888 - 8897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-i. Miyazaki, Y. Okada, O. Yamanaka, A. Kitano, K. Ikeda, S. Kon, T. Uede, S. R. Rittling, D. T. Denhardt, W. W.-Y. Kao, et al.
Corneal Wound Healing in an Osteopontin-Deficient Mouse
Invest. Ophthalmol. Vis. Sci.,
April 1, 2008;
49(4):
1367 - 1375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Carlson, M. Lin, C.-Y. Liu, W. W-Y. Kao, V. L. Perez, and E. Pearlman
Keratocan and Lumican Regulate Neutrophil Infiltration and Corneal Clarity in Lipopolysaccharide-induced Keratitis by Direct Interaction with CXCL1
J. Biol. Chem.,
December 7, 2007;
282(49):
35502 - 35509.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Wu, N. Vij, L. Roberts, S. Lopez-Briones, S. Joyce, and S. Chakravarti
A Novel Role of the Lumican Core Protein in Bacterial Lipopolysaccharide-induced Innate Immune Response
J. Biol. Chem.,
September 7, 2007;
282(36):
26409 - 26417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kucerova, J. Ou, D. Lawson, L. J. Leiper, and J. M. Collinson
Cell Surface Glycoconjugate Abnormalities and Corneal Epithelial Wound Healing in the Pax6+/- Mouse Model of Aniridia-Related Keratopathy
Invest. Ophthalmol. Vis. Sci.,
December 1, 2006;
47(12):
5276 - 5282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, K. Ikeda, O. Yamanaka, K. C. Flanders, Y. Okada, T. Miyamoto, A. Kitano, A. Ooshima, Y. Nakajima, Y. Ohnishi, et al.
Loss of Tumor Necrosis Factor {alpha} Potentiates Transforming Growth Factor {beta}-mediated Pathogenic Tissue Response during Wound Healing
Am. J. Pathol.,
June 1, 2006;
168(6):
1848 - 1860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Beecher, C. Carlson, B. R. Allen, R. Kipchumba, G. W. Conrad, K. M. Meek, and A. J. Quantock
An X-Ray Diffraction Study of Corneal Structure in Mimecan-Deficient Mice
Invest. Ophthalmol. Vis. Sci.,
November 1, 2005;
46(11):
4046 - 4049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Talusan, S. Bedri, S. Yang, T. Kattapuram, N. Silva, P. J. Roughley, and J. R. Stone
Analysis of Intimal Proteoglycans in Atherosclerosis-prone and Atherosclerosis-resistant Human Arteries by Mass Spectrometry
Mol. Cell. Proteomics,
September 1, 2005;
4(9):
1350 - 1357.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lefebvre-Lavoie, J. G. Lussier, and C. L. Theoret
Profiling of differentially expressed genes in wound margin biopsies of horses using suppression subtractive hybridization
Physiol Genomics,
July 14, 2005;
22(2):
157 - 170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. C. Carlson, C.-Y. Liu, T.-i. Chikama, Y. Hayashi, C. W.-C. Kao, D. E. Birk, J. L. Funderburgh, J. V. Jester, and W. W.-Y. Kao
Keratocan, a Cornea-specific Keratan Sulfate Proteoglycan, Is Regulated by Lumican
J. Biol. Chem.,
July 8, 2005;
280(27):
25541 - 25547.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, K. Ikeda, O. Yamanaka, T. Miyamoto, Y. Ohnishi, M. Sato, Y. Muragaki, A. Ooshima, Y. Nakajima, W. W.-Y. Kao, et al.
Expression of Smad7 in Mouse Eyes Accelerates Healing of Corneal Tissue after Exposure to Alkali
Am. J. Pathol.,
May 1, 2005;
166(5):
1405 - 1418.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-K. Yeh, W.-L. Chen, W. Li, E. M. Espana, J. Ouyang, T. Kawakita, W. W.-Y. Kao, S. C. G. Tseng, and C.-Y. Liu
Soluble Lumican Glycoprotein Purified from Human Amniotic Membrane Promotes Corneal Epithelial Wound Healing
Invest. Ophthalmol. Vis. Sci.,
February 1, 2005;
46(2):
479 - 486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Vij, L. Roberts, S. Joyce, and S. Chakravarti
Lumican Regulates Corneal Inflammatory Responses by Modulating Fas-Fas Ligand Signaling
Invest. Ophthalmol. Vis. Sci.,
January 1, 2005;
46(1):
88 - 95.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, Y. Muragaki, Y. Okada, T. Miyamoto, Y. Ohnishi, A. Ooshima, and W. W.-Y. Kao
Sonic Hedgehog Expression and Role in Healing Corneal Epithelium
Invest. Ophthalmol. Vis. Sci.,
August 1, 2004;
45(8):
2577 - 2585.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, S. Kono-Saika, Y. Ohnishi, M. Sato, Y. Muragaki, A. Ooshima, K. C. Flanders, J. Yoo, M. Anzano, C.-Y. Liu, et al.
Smad3 Signaling Is Required for Epithelial-Mesenchymal Transition of Lens Epithelium after Injury
Am. J. Pathol.,
February 1, 2004;
164(2):
651 - 663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, Y. Okada, T. Miyamoto, O. Yamanaka, Y. Ohnishi, A. Ooshima, C.-Y. Liu, D. Weng, and W. W.-Y. Kao
Role of p38 MAP Kinase in Regulation of Cell Migration and Proliferation in Healing Corneal Epithelium
Invest. Ophthalmol. Vis. Sci.,
January 1, 2004;
45(1):
100 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Y. Liu, D. E. Birk, J. R. Hassell, B. Kane, and W. W.-Y. Kao
Keratocan-deficient Mice Display Alterations in Corneal Structure
J. Biol. Chem.,
June 6, 2003;
278(24):
21672 - 21677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chakravarti, J. Paul, L. Roberts, I. Chervoneva, A. Oldberg, and D. E. Birk
Ocular and Scleral Alterations in Gene-Targeted Lumican-Fibromodulin Double-Null Mice
Invest. Ophthalmol. Vis. Sci.,
June 1, 2003;
44(6):
2422 - 2432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, T. Miyamoto, S.-i. Tanaka, T. Tanaka, I. Ishida, Y. Ohnishi, A. Ooshima, T. Ishiwata, G. Asano, T.-i. Chikama, et al.
Response of Lens Epithelial Cells to Injury: Role of Lumican in Epithelial-Mesenchymal Transition
Invest. Ophthalmol. Vis. Sci.,
May 1, 2003;
44(5):
2094 - 2102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Cao, N. Said, H. K. Wu, I. Kuwabara, F.-T. Liu, and N. Panjwani
Galectin-7 as a Potential Mediator of Corneal Epithelial Cell Migration
Arch Ophthalmol,
January 1, 2003;
121(1):
82 - 86.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Saika, T Miyamoto, I Ishida, K Shirai, Y Ohnishi, A Ooshima, and J W McAvoy
TGF{beta}-Smad signalling in postoperative human lens epithelial cells
Br. J. Ophthalmol.,
December 1, 2002;
86(12):
1428 - 1433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. O. Akama, A. K. Misra, O. Hindsgaul, and M. N. Fukuda
Enzymatic Synthesis in Vitro of the Disulfated Disaccharide Unit of Corneal Keratan Sulfate
J. Biol. Chem.,
November 1, 2002;
277(45):
42505 - 42513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Jepsen, F. Wu, J. H. Peragallo, J. Paul, L. Roberts, Y. Ezura, A. Oldberg, D. E. Birk, and S. Chakravarti
A Syndrome of Joint Laxity and Impaired Tendon Integrity in Lumican- and Fibromodulin-deficient Mice
J. Biol. Chem.,
September 13, 2002;
277(38):
35532 - 35540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Austin, C. Coulon, C.-Y. Liu, W. W.-Y. Kao, and J. A. Rada
Altered Collagen Fibril Formation in the Sclera of Lumican-Deficient Mice
Invest. Ophthalmol. Vis. Sci.,
June 1, 2002;
43(6):
1695 - 1701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Saika, T. Miyamoto, T. Tanaka, I. Ishida, Y. Ohnishi, and A. Ooshima
Latent TGFbeta binding protein-1 and fibrillin-1 in human capsular opacification and in cultured lens epithelial cells
Br. J. Ophthalmol.,
November 1, 2001;
85(11):
1362 - 1366.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Quantock, K. M. Meek, and S. Chakravarti
An X-ray Diffraction Investigation of Corneal Structure in Lumican-Deficient Mice
Invest. Ophthalmol. Vis. Sci.,
July 1, 2001;
42(8):
1750 - 1756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chakravarti, W. M. Petroll, J. R. Hassell, J. V. Jester, J. H. Lass, J. Paul, and D. E. Birk
Corneal Opacity in Lumican-Null Mice: Defects in Collagen Fibril Structure and Packing in the Posterior Stroma
Invest. Ophthalmol. Vis. Sci.,
October 1, 2000;
41(11):
3365 - 3373.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. Grover, C.-Y. Liu, W. W.-Y. Kao, and P. J. Roughley
Analysis of the Human Lumican Gene Promoter
J. Biol. Chem.,
December 22, 2000;
275(52):
40967 - 40973.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|